Atara Biotherapeutics, Inc.

ATRA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
216
SEC Filings

Business Summary

PART I Item 1. B usiness Overview Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel (tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regul...

Next Earnings

Q2 FY2026 — expected 2026-09-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionATRAdiscussed_in_filing Cybersecurity
topic_mentionATRAdiscussed_in_filing Cybersecurity
topic_mentionATRAdiscussed_in_filing Healthcare & Bio
topic_mentionATRAdiscussed_in_filing Platform & Ecosystem
topic_mentionATRAdiscussed_in_filing Healthcare & Bio
topic_mentionATRAdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001193125-26-108361EDGAR106K words
2025-03-072024-12-310000950170-25-035507EDGAR—
2024-03-282023-12-310000950170-24-037644EDGAR—
2023-02-082022-12-310000950170-23-002185EDGAR—
2022-02-282021-12-310001564590-22-007633EDGAR—
2021-03-012020-12-310001564590-21-009854EDGAR—
2020-02-272019-12-310001564590-20-007027EDGAR—
2019-02-262018-12-310001564590-19-004275EDGAR—
2018-02-272017-12-310001564590-18-003390EDGAR—
2017-03-092016-12-310001564590-17-003792EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-276219EDGAR71K words
2025-08-112025-06-300000950170-25-106550EDGAR—
2025-05-152025-03-310000950170-25-072040EDGAR—
2024-11-122024-09-300000950170-24-125389EDGAR—
2024-08-122024-06-300000950170-24-095533EDGAR—
2024-05-092024-03-310000950170-24-056959EDGAR—
2023-11-012023-09-300000950170-23-057147EDGAR—
2023-08-082023-06-300000950170-23-039820EDGAR—
2023-05-082023-03-310000950170-23-018820EDGAR—
2022-11-082022-09-300000950170-22-023248EDGAR—
2022-08-082022-06-300000950170-22-015536EDGAR—
2022-05-052022-03-310001564590-22-018253EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-160001193125-26-108344EDGAR2K words
2026-03-120001193125-26-103127EDGAR—
2026-03-030001193125-26-086793EDGAR—
2026-02-230001193125-26-062534EDGAR—
2026-01-120001193125-26-010342EDGAR—
2026-01-020001193125-26-000907EDGAR—
2025-11-120001193125-25-276209EDGAR—
2025-10-070001193125-25-232117EDGAR—
2025-09-040000950170-25-112898EDGAR—
2025-08-110000950170-25-106533EDGAR—

216 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001604464
TickerATRA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 4495c873e3c1fd98e605f7f930a0c7923868fc30b37219d02236ef2a814f95be
parent: ff509958c68b79b458fc4259bd9ad89985c4962fa35ddfb49588f6ae6c0f8ed8
content hash: 4092f96b6ce0d1ef2e98064de92532a25b0e17586633895ff0efd961f280681e
signed: 2026-04-13T04:43:47.581Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf